Abstract Phospholamban (PLN) is the endogenous inhibitor of the sarco(endo)plasmic reticulum Ca 2?
Introduction
Ca 2? ions signal muscle contraction and relaxation, coupling the membrane action potential and the mechanical contraction of muscle (Bers 2002; Kelly et al. 2008) . The interplay between the sarcoplasmic reticulum ATPase (SERCA) and phospholamban (PLN) is crucial to intracellular Ca 2? cycling and proper cardiac muscle contraction and relaxation, and dysfunction in their proteinprotein interactions have been implicated in cardiac disease (Haghighi et al. 2004) . SERCA is a 110 kDa integral membrane P-type ATPase which utilizes ATP hydrolysis to transport Ca 2? into the SR . SERCA is responsible for 70 % of the calcium reuptake during diastole in human cardiomyocytes . SERCA comprises a large cytoplasmic domain that includes the actuator domain, the phosphorylation domain, and a nucleotide binding domain, along with ten transmembrane helices constituting the Ca 2? transport pathway (Toyoshima et al. 2000) . The cardiac isoform of SERCA (SERCA2a) is regulated by PLN, a single-pass membrane protein that binds the enzyme via intramembrane interactions, reducing its apparent Ca 2? affinity (Simmerman and Jones 1998; Traaseth et al. 2008; Veglia et al. 2010) . b-Adrenergic stimulation unleashes protein kinase A (PKA) that phosphorylates PLN at Ser16, reversing its inhibition of SERCA and augmenting the diastolic phase (Bers 2008) .
PLN is a 52-amino acid integral membrane protein which is comprised of three structural domains (Traaseth et al. 2009; Verardi et al. 2011; Zamoon et al. 2003) that are further subdivided into four dynamic domains (cytoplasm: domain Ia (residues 1-16), loop (residues 17-22), domain Ib (residues 23-30); transmembrane: domain II (residues 31-52)) (Metcalfe et al. 2004; Traaseth et al. 2009; Verardi et al. 2011) (Fig. 1) . The transmembrane helix of PLN is the principle structural domain that inhibits SERCA (Karim et al. 2000; Karim et al. 2004) , while the regulatory phosphorylation Ser16 site, which determines the inhibitory or non-inhibitory state, lies in the cytoplasmic helix (Chu et al. 2000) . PLN can populate several conformational states, and domain Ia and Ib participate in folding/unfolding equilibria, which are important for SERCA inhibition as well as recognition by PKA (Gustavsson et al. 2011a, c; Masterson et al. 2011; Traaseth and Veglia 2010) . The loop connecting these two domains also has functional relevance, in particular the Pro21 residue that lies in the center of the loop. Squier and coworkers reported that mutation of Pro21 to Ala in a monomeric cysteine-null background led to partial inhibition of SERCA, increase in overall helicity, decreased dynamics at the C-terminus, and local structural changes at the loop leading to diminished solvent accessibility (Li et al. 2005) . Additionally, our group found that the SERCA inhibition and binding could be tuned modulating the conformational dynamics of the loop through mutation in the Pro21 site, via a so-called dynamic rheostat (Ha et al. 2007) . Our studies identified the mutant species AFA-PLN P21G to be a possible candidate for treatment of heart failure by delivery via rAAV gene therapy. AFA-PLN P21G was found to have the same structural dynamics and functional characteristics as PLN S16E , a PLN pseudophosphorylated mutant already proven to be successful in reversing heart failure in large and small animal models by Chien and coworkers (Hoshijima et al. 2002; Kaye et al. 2007) .
Naturally occurring mutations in PLN have also been linked to familial forms of cardiomyopathy: R9C (Schmitt et al. 2003) , R9L and R9H (Medeiros et al. 2011) , R14del (Haghighi et al. 2006) , and L39stop (Haghighi et al. 2003) . PLN has also become a target for gene therapy (Hoshijima et al. 2002; Hoshijima et al. 2006; Kaye et al. 2007 ), namely by delivering PLN mutants which decrease SERCA inhibition. The challenge remains in how to rationally design PLN mutants with tunable effects on SERCA to account for the diversity of patient population and the various manifestations of heart failure (Tilemann et al. 2012) .
Numerous mutagenesis studies of PLN have been carried out by the MacLennan, Jones, and Young groups, offering invaluable insight by identifying residues crucial to PLN's inhibitory ability Simmerman et al. 1996; Trieber et al. 2009 ). Although these studies served as a crucial starting point to understanding the effect of point mutations in PLN have on SERCA activity, they often did not identify the reasons for observed functional effects, i.e., whether the mutation induced a change to structural dynamics, altered the binding surface, decreased SERCA binding, etc. The data clearly demonstrate that the transmembrane domain is Janus-faced, with one side of the helix primarily involved in oligomerization and the other side binding to SERCA. Mutagenesis studies show that domain Ia and the loop are the optimum targets for designing loss-of-function (LOF) mutants. In contrast, mutations in domain Ib and domain II yield varying results, but all known gain-of-function (GOF) and super-inhibitors are concentrated in those two domains.
The rationale of this study is to build on our previous success tuning the structural dynamics of PLN to control SERCA function by introducing a series of glycine residues to the loop domain. Our original hypothesis was that an increase in conformational dynamics in the loop would interrupt the structural coupling between the transmembrane helix, which is primarily responsible for SERCA inhibition, and the cytoplasmic helix, which contains the phosphorylation sites that dictate the inhibition state. To test this hypothesis, we sought to introduce single Gly mutations at the M20 site and Q22 site to investigate whether the LOF rendered by the P21G mutation was sitespecific (Fig. 2) . Secondly, we determined the SERCA inhibition of the phosphorylated species to see if posttranslational control of these single Gly-mutants of PLN still remains intact, a property which has been suggested to be crucial for therapeutic success (Ha et al. 2007 ). Thirdly, we expanded the Gly mutations into double and triple mutations: AFA-PLN M20G P21G and AFA-PLN M20G P21G
Q22G . To characterize the conformational dynamics of the various mutants and correlate with their functional state, we used nuclear magnetic resonance (NMR) spectroscopy that enables one to probe molecular motions of proteins at the atomic level (Palmer et al. 2001 ).
Our results suggest that the structural dynamics of the glycine mutants can be tuned, resulting in varying degrees of fast timescale dynamics and degrees of SERCA inhibition. However, species where the mutation increased the conformational dynamics past the threshold set by the phosphorylated species behave as the transmembrane helix alone. The mutants represent new templates for rational design of protein therapies using gene transfer approaches, modifying the effects of an inhibitor to control enzyme function.
Materials and methods

Cloning of PLN mutants
Primary sequences of the mutants cloned in this study are described in Fig. 2 . Cloning was performed using the Stratagene QuikChange protocol as previously described (Ha et al. 2007 ). For the AFA-PLN M20G , AFA-PLN P21G , and AFA-PLN Q22G constructs, the pMal-c2E-TEV-AFA-PLN plasmid was used as a parental template, which expresses a maltose binding protein (MBP) PLN fusion protein with a tobacco etch virus (TEV) protease cleavage site encoded in-between. The forward primer for the AFA-PLN M20G is as follows: 5 0 -ACC ATT GAA GGC CCG CAG CAG GCG CGC CAG AAC-3 00 . The forward primer for the AFA-PLN Q22G is as follows: 5 0 -ACC ATT GAA ATG CCG GGC CAG GCG CGC CAG AAC-3 00 . The forward primer for the AFA-PLN M20G P21G is as follows: 5 0 -GGC AGC ACC ATT GAA GGC GGC CAG CAG GCG CGC CAG AAC CTG-3 00 . The cloning of GGG-PLN required two PCR reactions on the P21G PLN AFA background, first converting M20 to G and then Q22 to G. Pentameric mutants were cloned using the pMal-c2E-TEVwtPLN plasmid as the parental template. PLN M20G P21G was cloned stepwise, using PLN P21G as the initial template. Stepwise mutagenesis was necessitated due to the high T m values of primers containing codons encoding for glycine, because of their high GC content. After mutagenesis was confirmed from EtBr stained agarose gels, the PCR reaction was transformed into DH5a cells and grown on ampicillin-agarose plates. Subsequent colonies were grown overnight in 5 mL Luria-Bertani media with 0.1 % ampicillin, and then spun down on a tabletop centrifuge at 13,000 rpm. The remaining pellet was resuspended and the plasmid was extracted from the pellet using the Qiagen Quick-Spin Miniprep kit. Constructs were confirmed through sequencing at the University of Minnesota Biomedical Genomics Center. Correct target constructs were then transformed into BL21 (DE3) Escherichia coli cells.
Protein preparations and ATPase activity assays
Protein expression and purification of all constructs were performed as previously described (Buck et al. 2003; Veglia et al. 2010) . Phosphorylation of PLN samples at Ser16 was performed as previously described (Gustavsson et al. 2011a; Ha et al. 2007; Metcalfe et al. 2005 ) using recombinantly expressed protein kinase A purified by an established protocol . Phosphorylation was confirmed by a band shift in the SDS-PAGE, and by MALDI-TOF mass spectrometry. The degree of SERCA inhibition by PLN analogs was determined using a coupled enzyme assay correlating the depletion in NADH absorbance to ATPase activity as previously described (Fabiato and Fabiato 1978; Ha et al. 2007) . SERCA inhibition was measured in reconstituted lipid samples according to Reddy et al. (2003) . PLN variants were co-reconstituted with purified SERCA in lipid bilayer membranes (DOPC:DOPE, 4:1) at molar ratios of 10:1 PLN:SERCA and 700:1 lipids:SERCA. The calcium dependence of the ATPase activity was measured at 37°C using a coupled enzyme assay, monitoring the consumption of NADH by the decrease in absorbance at 340 nm using a Spectromax microplate reader (Molecular Devices). Initial rate of SERCA (V) was measured as a function of calcium concentration (pCa), and data was fit to the Hill equation (Reddy et al. 2003) .
NMR studies
Unless otherwise noted, NMR samples were prepared with a buffer containing 20 mM Na 2 HPO 4 (J.T. Baker), 120 mM NaCl (Malinkrodt), 0.1 % NaN 3 , and 300 mM dodecylphosphocholine (DPC) (Avertec). Lyophilized PLN was weighed and added in increments to 300 lL buffer until the sample reached an approximate concentration of 1-1.5 mM protein. After addition of HPLC purified protein, all samples were adjusted to pH 6.0 with dilute NaOH to neutralize residual trifluoroacetic acid remaining in the protein powder. All [ 1 H, 15 N] heteronuclear single quantum coherence (HSQC) spectra were collected on a Varian spectrometer operating at a 1 H Larmor frequency of 600 MHz. Sample quality was assessed by signal-to-noise and resolution in the 2D spectrum with between 32 and 64 increments in the indirect dimension. Heteronuclear steady-state NOE spectra were collected as previously described (Ha et al. 2007; Metcalfe et al. 2004 ). Briefly, two spectra were collected using the established pulse sequence based on Farrow et al. (1994) with a spectral width of 6,000 Hz in the indirect proton dimension and 1500 Hz in the indirect nitrogen dimension. 128 scans were done with 64 points in the indirect dimension. The saturation spectrum was collected with a 3 s presaturation period on the proton frequency. Peak intensities were analyzed using NMRView5 software (Johnson 2004) .
Results
Single Gly mutations were successfully cloned on a monomeric AFA-PLN background, yielding AFA-PLN M20G , AFA-PLN P21G , and AFA-PLN
Q22G
. The species were expressed in E. coli, and subsequently isolated by affinity and HPLC chromatography. SERCA activity measurements served as the initial screen to assess the effects of the mutations. Functional assays were performed with SERCA reconstituted in lipids alone as the negative control, and also in the presence of AFA-PLN or the superinhibitor mutant AFA-PLN N27A as a positive control, giving a consistent DpK Ca shift of 0.3 and 0.5 pCa units, respectively. Figure 3a displays a representative normalized ATPase activity curve which yields the pK Ca shifts. Fig. 3b shows the average DpK Ca values for the three mutants as compared to the control AFA-PLN (filled bars). Compared to the AFA-PLN species, the AFA-PLN M20G , AFA-PLN P21G , and AFA-PLN Q22G analogs reduced the PLN inhibition by approximately 0.1 pCa units. Therefore, irrespective of their positioning in the dynamic loop, the single site mutations manifested an LOF character. The extent of this effect is variable, with a gradient of SERCA inhibition ranging from DpK Ca of 0.23 ± 0.01 for M20G to DpK Ca of 0.16 ± 0.02 for Q22G. Remarkably, previous studies showed that Ala mutations of M20 or Q22 do not render LOF characteristics MacLennan and Kranias 2003) .
To test their propensity to be phosphorylated by protein kinase A (PKA-C) and thereby reverse SERCA inhibition, the Gly mutants of PLN were incubated with catalytic amounts of the kinase and analyzed by gel shift assays. We found that all of the single Gly PLN mutants were quantitatively phosphorylated in vitro by recombinant protein kinase A. Importantly, SERCA functional assays revealed that phosphorylation at Ser16 for each single Gly mutant was sufficient to reverse inhibition (Fig. 3b, open bars) .
To investigate whether the combination of two or more Gly mutations would increase the LOF effect, we cloned a double mutant, AFA-PLN M20G P21G , and a triple Gly mutant, AFA-PLN M20G P21G Q22G
. We found that (1) the AFA-PLN M20G P21G species was a complete LOF mutant, and (2) AFA-PLN M20G P21G Q22G completely recovers the inhibitory function (Fig. 3b) . Based on these results, we speculate that combining the Gly at position M20 and P21 conferred even stronger LOF behavior, creating an additive effect in the double mutant. In contrast, a triple mutation eliminated the structural coupling between the cytoplasmic and transmembrane helix, resulting in a species that is similar to the transmembrane helix alone (Karim et al. 2000) . Electrophoretic gel shift assays show that incubation of PKA with these double and triple mutants does result in a gel shift typically observed for the phosphorylated species, consistent with quantitative phosphorylation. These results were confirmed by mass spectrometry. The cytoplasmic helix contains the phosphorylation site, while the transmembrane helix is the principle domain responsible for inhibition. We sought to test the hypothesis that phosphorylation of the Gly mutants would not reverse the effects of inhibition, due to the possible breaking of the conformational coupling between these domains. Our results indicate that phosphorylation does reverse the effects of inhibition for PLN M20G P21G and also PLN M20G P21G Q22G . Figure 3b shows the averaged SERCA activity measurements of several different samples of unphosphorylated (closed bars) and phosphorylated (open bars) of the double and triple glycine AFA-PLN loop mutations. Values of DpK Ca are reported in Table 1 . A critical issue in the design of possible therapeutic mutations for delivery through gene therapy is the effect the species will have in vitro versus in vivo, particularly when dealing with possible functional effects that are the result of unknown protein-protein interactions and also interactions with the endogenous species. Hence, we studied the function of mutant with the most LOF character, AFA-PLN M20G P21G by comparison to the endogenous wild-type background sequence in order to determine whether the functional results may be due to altered oligomeric states. Functional results with SERCA in the presence of the PLN M20G P21G mutant show that this is a strong LOF mutant, with a DpK Ca of 0.095 ± 0.021 (Fig. 3a, right) Supplementary Fig. 1a ) and assigned using 15 N edited NOESY-HSQC experiments at short (70 ms) mixing times to identify short-range NOEs. Amide resonance assignments were correlated to the 1 H-15 N HSQC assignment for AFA-PLN (Supplementary Fig. 1b) . Most changes are localized near the mutation site. However, some distal changes, especially in domain Ib, are detected, specifically residues Arg25 and Asn27.
The structural dynamics of these mutations were characterized using nuclear spin relaxation measurements (Palmer et al. 2001 , and AFA-PLN M20G P21G Q22G ( Supplementary Fig. 2 ) in DPC micelles. While the structure is largely intact, as evidenced by only minor perturbations in the 1 H-15 N HSQC spectrum compared to AFA-PLN, we do observe an increase in the fast (ps-ns) conformational dynamics of the backbone for all of the mutants examined. Increased motions are detected in the intervening loop and domains Ia and Ib. While domain Ib and the loop of the Gly mutants have conformational dynamics similar to that of pSer16 AFA-PLN, the phosphorylated species is significantly more mobile in domain Ia. Thus, introduction of the single or multiple Gly mutants change only the local motion and does not mimic the conformational dynamics found in the phosphorylated species (pSer16-AFA-PLN). A possible explanation is that the negatively charged phosphoserine interacts with the positively charged side chains of Arg13 and 14, forming transient salt bridges that affect the folding and dynamics of the entire cytoplasmic regions including domain Ia. In fact, the presence of the phosphoryl group shifts the conformational equilibrium of domain Ia of PLN from a folded (T state) to an unfolded (R state) (Gustavsson et al. 2011a; Masterson et al. 2011) . The 15 N relaxation data do not support a significant T to R state transition upon Gly mutations. The latter was confirmed by 1 H-13 C HSQC experiments that image the side chains bearing methyl groups. Indeed, we found that the Gly mutations in the loop do not affect the T to R state equilibrium substantially, i.e. we observed only minor chemical shift changes for the domain Ia methyl groups (Supplementary Fig 3) . These findings indicate that the LOF character of the Gly mutants is not directly related to the T/R equilibrium of domain Ia, and that the Gly mutations in the intervening loop cause a local increase in backbone flexibility.
Discussion
We sought to expand on previously published results on tuning the function of SERCA by altering the conformational dynamics of the loop domain in PLN (Ha et al. 2007 ). Our previous results showed that AFA-PLN P21G displayed similar structural dynamics to the pseudo-phosphorylated species PLN S16E , which has shown promise in reversing heart failure in animal models upon delivery via rAAV-mediated gene therapy (Hoshijima et al. 2006) . In addition to mimicking the structural dynamics of the pseudo-phosphorylated form, AFA-PLN P21G also has the additional characteristic of being able to be post-translationally modified by phosphorylation at Ser16 by PKA, a regulatory feature which is crucial for maintaining Ca 2?
homeostasis (Ha et al. 2011) .
The functional results of AFA-PLN
M20G
, AFA-PLN P21G , and AFA-PLN Q22G (Fig 3, Table 1 ) show that introduction of the Gly residue did not need to be specifically positioned at Pro 21 in order to have a LOF effect. Additionally, the in vitro phosphorylation results of the three species suggest that these mutants may still also be post-translationally modified in vivo. Remarkably, similar alanine mutations at M20 and Q22 did not show appreciable differences in SERCA inhibition , demonstrating the sensitivity of SERCA activity on the PLN sequence. While all of the mutants resulted in LOF characteristics, they inhibited SERCA to different degrees, resulting in a gradient of function. This is an important factor when designing mutations to alter contractility. While introducing PLN mutants which are completely LOF would increase SERCA activity and activate diastole in the short term, constitutive activation of SERCA is known to promote hypertrophy (Shanmugam et al. 2011 ) and a PLN null genotype is found in humans to result in heart failure (Haghighi et al. 2003; Medeiros et al. 2011) . Hence, development of mutations of PLN for use in gene therapy would necessitate mutants which sampled a wide array of levels in SERCA inhibition.
The results of AFA-PLN M20G P21G show that the LOF effects for the M20 and P21 site were additive, resulting in the least inhibitory mutant of this study. Phosphorylation of this species resulted in a DpK Ca similar to that of pSer16 AFA-PLN. The NMR results show minimal differences in the average structures of the various mutants. In fact, comparison of the protein fingerprints ([ 1 H, 15 N] HSQC spectra) of the AFA-PLN M20G P21G mutant and AFA-PLN show only some slight differences, especially in residues near the mutation site in the primary sequence. A few differences are also evident for residues located in the juxta membrane domain Ib (Fig. 1) . A map of the chemical shift changes upon increasing glycines in the loop did not follow the same trajectory that was seen for pseudophosphorylated mutants and the Ser16 phosphorylated species (Gustavsson et al. 2011a) . Also, the NMR dynamic parameters (R 1 , R 2 and heteronuclear NOE values) in domain Ia indicate that AFA PLN M20G P21G is significantly less dynamic than pSer16 AFA-PLN in this domain ( Supplementary Fig 2) . Still, AFA-PLN M20G P21G mimics pSer16-PLN functionally, which suggests that mutations in the loop leads to the reversal of SERCA inhibition by a different mechanism that an order-to-disorder transition of domain Ia, a mechanism that has been proposed for phosphorylated and pseudo-phosphorylated mutants of PLN (Gustavsson et al. 2011a) . In contrast to domain Ia, the conformational dynamics of the loop and domain Ib of the Gly mutants are similar to that of pSer16 PLN and thus more mobile than AFA-PLN. Taken together with the chemical shift changes in domain Ib, this alteration of domain Ib conformational dynamics may be responsible for the functional effects associated with the Gly mutations.
Based on the data collected on these single, double, and triple Gly mutants, we hypothesize that the functional effects of the Gly mutations are related to a gradual structural uncoupling of the two helical domains of PLN: the inhibitory transmembrane domain and the regulatory cytoplasmic regions. A single Gly mutation increases the local dynamics and induces LOF character. Also, a double mutation augments the LOF character with concomitant increase of local dynamics. However, three sequential mutations cause a complete loss of the structural coupling between the regulatory cytoplasmic domain and the inhibitory transmembrane domain, rendering the mutant similar to the isolated transmembrane domain, which has an inhibitory potency similar to that of PLN (Karim et al. 2000) . To support this hypothesis, we showed that single and double Gly mutants have increasing LOF character, while the inhibitory potency of the triple Gly mutant is virtually identical to that of AFA-PLN. Interestingly, AFA-PLN M20G P21G Q22G can still be phosphorylated, reversing SERCA inhibition. The substitution of the three Gly residues in the loop does not prevent the signal of phosphorylation to be relayed from PLN to SERCA to reverse its inhibition. This suggests that phosphorylation is a more complex event that involves both structural and electrostatic changes in both binding partners, with a possible allosteric mechanism where interactions of the phosphorylated domain Ia lead to changes within SERCA that are relayed to domain II. The latter will be resolved when atomic resolution structural information on the SERCA/PLN will be available.
Although the original Ala-scanning experiments performed by MacLennan et al. (1998) show Ala mutations in the loop region to be non-effectual on SERCA function (with the exception of P21A), Gly mutations in the same region reveal that fairly conservative alterations in the loop region can have a significant impact on SERCA function. Figure 4 shows a structural dynamics and function correlation between different species of PLN, and the blue triangle highlights the optimum area to target when designing LOF mutants to improve cardiac contractility by improving SERCA function. The results of this study are promising in revealing the loop region as an area to target for development of therapeutic PLN mutants, since the phosphorylation site remains intact. The results of studying PLN mutations have established that for a mutant to maintain proper function: (a) it must be able to be phosphorylated in order to relieve inhibition, and (b) the dynamic changes throughout domain Ia, the loop, and domain Ib can mimic the order-to-disorder transition induced by phosphorylation, but they should not exceed the dynamics of pSer16 PLN. 
